Journal article
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer
P Sooriakumaran, HM Coley, SB Fox, P Macanas-Pirard, DP Lovell, A Henderson, CG Eden, PD Miller, SEM Langley, RW Laing
Anticancer Research | INT INST ANTICANCER RESEARCH | Published : 2009
Abstract
Cyclooxygenase-2 (COX-2) is associated with tumour promotion, inhibition of apoptosis, angiogenesis and metastasis. Celecoxib, a selective COX-2 inhibitor was investigated, in patients with clinically localized prostate cancer using immunohistochemistry. Patients and Methods: Patients with cT1-2 prostate cancer (n=45) were randomized to celecoxib 400mg b.d. or no treatment for four weeks prior to radical prostatectomy. Histological sections of preoperative biopsy and matched radical prostatectomy specimens were stained for markers of cell proliferation (MIB-1/Ki-67), microvessel density (CD-31 with Weidner scoring), COX-2, apoptosis (TUNEL analysis), angiogenic factors (VEGF and KDR) and HIF..
View full abstractGrants
Awarded by Prostate Project
Awarded by University of Surrey Pump Priming Fund
Funding Acknowledgements
We thank The Prostate Project (UK registered charity number 1078523) and the University of Surrey Pump Priming Fund (bid RS48/04) for financial support which enabled this work to be carried out. Also, thanks go to research nurses Ms Donna Higgins and Ms Claire Deering for their assistance in recruitment of patients for this study.